Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.01
MDAS's Cash to Debt is ranked lower than
65% of the 1737 Companies
in the Global Health Information Services industry.

( Industry Median: 4.76 vs. MDAS: 0.01 )
MDAS' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 0.01

Equity to Asset 0.30
MDAS's Equity to Asset is ranked lower than
57% of the 1699 Companies
in the Global Health Information Services industry.

( Industry Median: 0.59 vs. MDAS: 0.30 )
MDAS' s 10-Year Equity to Asset Range
Min: -0.6   Max: 0.61
Current: 0.3

-0.6
0.61
Interest Coverage 1.93
MDAS's Interest Coverage is ranked lower than
63% of the 1140 Companies
in the Global Health Information Services industry.

( Industry Median: 742.12 vs. MDAS: 1.93 )
MDAS' s 10-Year Interest Coverage Range
Min: 0.59   Max: 9999.99
Current: 1.93

0.59
9999.99
F-Score: 7
Z-Score: 1.04
M-Score: -2.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 13.68
MDAS's Operating margin (%) is ranked higher than
86% of the 1731 Companies
in the Global Health Information Services industry.

( Industry Median: 5.56 vs. MDAS: 13.68 )
MDAS' s 10-Year Operating margin (%) Range
Min: -4.99   Max: 17.56
Current: 13.68

-4.99
17.56
Net-margin (%) 4.23
MDAS's Net-margin (%) is ranked higher than
70% of the 1731 Companies
in the Global Health Information Services industry.

( Industry Median: 3.87 vs. MDAS: 4.23 )
MDAS' s 10-Year Net-margin (%) Range
Min: -8.21   Max: 16.69
Current: 4.23

-8.21
16.69
ROE (%) 6.06
MDAS's ROE (%) is ranked higher than
67% of the 1695 Companies
in the Global Health Information Services industry.

( Industry Median: 6.78 vs. MDAS: 6.06 )
MDAS' s 10-Year ROE (%) Range
Min: -7.36   Max: 20.26
Current: 6.06

-7.36
20.26
ROA (%) 1.79
MDAS's ROA (%) is ranked higher than
61% of the 1743 Companies
in the Global Health Information Services industry.

( Industry Median: 3.80 vs. MDAS: 1.79 )
MDAS' s 10-Year ROA (%) Range
Min: -2.45   Max: 14.99
Current: 1.79

-2.45
14.99
ROC (Joel Greenblatt) (%) 59.74
MDAS's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 1737 Companies
in the Global Health Information Services industry.

( Industry Median: 30.27 vs. MDAS: 59.74 )
MDAS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -28.34   Max: 148.36
Current: 59.74

-28.34
148.36
Revenue Growth (%) 17.10
MDAS's Revenue Growth (%) is ranked higher than
87% of the 1428 Companies
in the Global Health Information Services industry.

( Industry Median: 6.40 vs. MDAS: 17.10 )
MDAS' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 23.6
Current: 17.1

0
23.6
EBITDA Growth (%) 72.30
MDAS's EBITDA Growth (%) is ranked higher than
98% of the 1159 Companies
in the Global Health Information Services industry.

( Industry Median: 8.30 vs. MDAS: 72.30 )
MDAS' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 72.3
Current: 72.3

0
72.3
» MDAS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

MDAS Guru Trades in Q3 2013

Mario Gabelli 9,500 sh (New)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Jim Simons 232,300 sh (-39.38%)
» More
Q4 2013

MDAS Guru Trades in Q4 2013

Steven Cohen 715,676 sh (New)
Joel Greenblatt 25,660 sh (New)
Paul Tudor Jones 35,826 sh (New)
Jim Simons 309,800 sh (+33.36%)
Mario Gabelli Sold Out
» More
Q1 2014

MDAS Guru Trades in Q1 2014

Mario Gabelli 11,500 sh (New)
Steven Cohen 1,099,241 sh (+53.59%)
Joel Greenblatt 34,198 sh (+33.27%)
Paul Tudor Jones Sold Out
Jim Simons 60,300 sh (-80.54%)
» More
Q2 2014

MDAS Guru Trades in Q2 2014

Paul Tudor Jones 9,800 sh (New)
Joel Greenblatt 52,010 sh (+52.08%)
Steven Cohen 245,600 sh (unchged)
Mario Gabelli 11,500 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MDAS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Add 52.08%0.01%$22.02 - $25.42 $ 20.8-11%52010
Mario Gabelli 2014-03-31 New Buy$19.58 - $25.74 $ 20.8-7%11500
Joel Greenblatt 2014-03-31 Add 33.27%$19.58 - $25.74 $ 20.8-7%34198
Joel Greenblatt 2013-12-31 New Buy0.01%$19.61 - $26.39 $ 20.8-8%25660
Mario Gabelli 2013-12-31 Sold Out $19.61 - $26.39 $ 20.8-8%0
Joel Greenblatt 2013-09-30 Sold Out 0.03%$17.49 - $25.42 $ 20.8-7%0
Mario Gabelli 2013-09-30 New Buy$17.49 - $25.42 $ 20.8-7%9500
Joel Greenblatt 2013-06-30 New Buy0.03%$16.4 - $19.14 $ 20.816%38584
George Soros 2011-12-31 Sold Out 0.0022%$8.91 - $12.32 $ 20.8110%0
George Soros 2011-09-30 New Buy$9.4 - $13.99 $ 20.884%13400
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 44.50
MDAS's P/E(ttm) is ranked higher than
69% of the 1856 Companies
in the Global Health Information Services industry.

( Industry Median: 47.20 vs. MDAS: 44.50 )
MDAS' s 10-Year P/E(ttm) Range
Min: 36.57   Max: 1500.77
Current: 44.5

36.57
1500.77
P/B 2.70
MDAS's P/B is ranked higher than
68% of the 1856 Companies
in the Global Health Information Services industry.

( Industry Median: 2.84 vs. MDAS: 2.70 )
MDAS' s 10-Year P/B Range
Min: 1.26   Max: 4.39
Current: 2.7

1.26
4.39
P/S 1.90
MDAS's P/S is ranked higher than
70% of the 1856 Companies
in the Global Health Information Services industry.

( Industry Median: 2.33 vs. MDAS: 1.90 )
MDAS' s 10-Year P/S Range
Min: 0.92   Max: 4.22
Current: 1.9

0.92
4.22
PFCF 17.30
MDAS's PFCF is ranked higher than
88% of the 1856 Companies
in the Global Health Information Services industry.

( Industry Median: 2482.00 vs. MDAS: 17.30 )
MDAS' s 10-Year PFCF Range
Min: 5.2   Max: 46.77
Current: 17.3

5.2
46.77
EV-to-EBIT 21.77
MDAS's EV-to-EBIT is ranked higher than
74% of the 1856 Companies
in the Global Health Information Services industry.

( Industry Median: 33.78 vs. MDAS: 21.77 )
MDAS' s 10-Year EV-to-EBIT Range
Min: 19.7   Max: 47
Current: 21.77

19.7
47
PEG 1.35
MDAS's PEG is ranked higher than
91% of the 1856 Companies
in the Global Health Information Services industry.

( Industry Median: 9999.00 vs. MDAS: 1.35 )
MDAS' s 10-Year PEG Range
Min: 1.56   Max: 224
Current: 1.35

1.56
224
Shiller P/E 548.40
MDAS's Shiller P/E is ranked higher than
75% of the 1856 Companies
in the Global Health Information Services industry.

( Industry Median: 9999.00 vs. MDAS: 548.40 )
MDAS' s 10-Year Shiller P/E Range
Min: 71.15   Max: 2571
Current: 548.4

71.15
2571
Current Ratio 0.63
MDAS's Current Ratio is ranked lower than
61% of the 1723 Companies
in the Global Health Information Services industry.

( Industry Median: 1.90 vs. MDAS: 0.63 )
MDAS' s 10-Year Current Ratio Range
Min: 0.55   Max: 2.77
Current: 0.63

0.55
2.77
Quick Ratio 0.63
MDAS's Quick Ratio is ranked lower than
60% of the 1723 Companies
in the Global Health Information Services industry.

( Industry Median: 1.78 vs. MDAS: 0.63 )
MDAS' s 10-Year Quick Ratio Range
Min: 0.55   Max: 2.77
Current: 0.63

0.55
2.77

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 0.95
MDAS's Price/DCF (Projected) is ranked higher than
91% of the 1856 Companies
in the Global Health Information Services industry.

( Industry Median: 6.50 vs. MDAS: 0.95 )
MDAS' s 10-Year Price/DCF (Projected) Range
Min: 0.71   Max: 1.72
Current: 0.95

0.71
1.72
Price/Median PS Value 0.95
MDAS's Price/Median PS Value is ranked higher than
81% of the 1856 Companies
in the Global Health Information Services industry.

( Industry Median: 1.17 vs. MDAS: 0.95 )
MDAS' s 10-Year Price/Median PS Value Range
Min: 0.46   Max: 1.97
Current: 0.95

0.46
1.97
Price/Peter Lynch Fair Value 1.77
MDAS's Price/Peter Lynch Fair Value is ranked higher than
91% of the 1856 Companies
in the Global Health Information Services industry.

( Industry Median: 9999.00 vs. MDAS: 1.77 )
MDAS' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.88   Max: 213.89
Current: 1.77

1.88
213.89
Earnings Yield (Greenblatt) 4.60
MDAS's Earnings Yield (Greenblatt) is ranked higher than
63% of the 1476 Companies
in the Global Health Information Services industry.

( Industry Median: 5.70 vs. MDAS: 4.60 )
MDAS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.1   Max: 5.1
Current: 4.6

2.1
5.1
Forward Rate of Return (Yacktman) 32.82
MDAS's Forward Rate of Return (Yacktman) is ranked higher than
94% of the 1311 Companies
in the Global Health Information Services industry.

( Industry Median: 5.18 vs. MDAS: 32.82 )
MDAS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -8.9   Max: 33.7
Current: 32.82

-8.9
33.7

Business Description

Industry: Application Software » Health Information Services
Compare: » details
Traded in other countries:58M.Germany
Medassets, Inc. was incorporated in 1999. The Company provides technology-enabled products and services which together help mitigate the increasing financial pressures faced by hospitals and health systems. These include the increasing complexity of healthcare reimbursement, rising levels of bad debt and uncompensated care and significant increases in supply utilization and operating costs. Its solutions are designed to improve operating margin and cash flow for hospitals and health systems. The sustainable financial improvements provided by its solutions occur in a matter of months and can be quantified and confirmed by its customers. Its solutions integrate with its customers' existing operations and enterprise software systems and require minimal upfront costs or capital expenditures. The sustainable financial improvements provided by its solutions occur in a matter of months and can be quantified and confirmed by its customers. The Company delivers its solutions through two business segments, Revenue Cycle Management (RCM) and Spend Management (SM). Its RCM segment provides a comprehensive suite of products and services spanning the hospital revenue cycle workflow — from patient access and financial responsibility, charge capture and integrity, pricing analysis, claims processing and denials management, pay or contract management, revenue recovery and accounts receivable services. Its workflow solutions, together with its data management, decision support, performance analytics, and compliance and audit tools, increase revenue capture and cash collections, reduce accounts receivable balances and increase regulatory compliance. Its SM segment provides a comprehensive suite of technology-enabled services that help its customers manage their non-labor expense categories. Its solutions lower supply and medical device costs and utilization by managing the procurement process through its group purchasing organization's portfolio of contracts, consulting services and business analytics and intelligence tools. Its Spend Management segment helps its customers manage their non-labor expense categories through a combination of group purchasing, performance improvement consulting, including implantable physician preference items, or PPI, cost and utilization management and service line consulting, and business intelligence tools. The market for its products and services is fragmented, intensely competitive. The Company is highly regulated and is subject to changing political, legislative, regulatory and other influences.
» More Articles for MDAS

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Amazon.com Inc, Atmel Corporation, Monolithic Power Systems Inc, MedAsse Nov 10 2013 
Steven Cohen Increases Two High-Growth Positions - OCZ Technology and MedAssets Inc. Apr 17 2012 
MEDASSETS, INC. (MDAS) COO Rand A Ballard sells 9,000 Shares Mar 08 2011 
MEDASSETS, INC. Reports Operating Results (10-K) Mar 01 2011 
MEDASSETS, INC. (MDAS) COO Rand A Ballard sells 15,000 Shares Feb 09 2011 
MEDASSETS, INC. (MDAS) COO Rand A Ballard sells 15,000 Shares Jan 05 2011 
MEDASSETS, INC. (MDAS) COO Rand A Ballard sells 15,000 Shares Dec 08 2010 
MEDASSETS, INC. (MDAS) Chairman, President and CEO John A Bardis sells 40,000 Shares Dec 01 2010 
MEDASSETS, INC. (MDAS) COO Rand A Ballard sells 15,000 Shares Nov 09 2010 
MEDASSETS, INC. (MDAS) COO Rand A Ballard sells 15,000 Shares Oct 07 2010 


More From Other Websites
MedAssets Closes Sg2 Acquisition for $142M but Shares Fall Sep 24 2014
MEDASSETS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial... Sep 22 2014
MedAssets Completes Acquisition of Sg2 Sep 22 2014
MEDASSETS INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under... Sep 12 2014
MedAssets Announces Call for Speakers for 2015 Healthcare Business Summit Sep 11 2014
Taking Stock: Baird’s Skorney on Developing ‘Hot Drug’ Sep 10 2014
Baylor Scott & White Health Chooses MedAssets for Procurement Operations Sep 08 2014
MedAssets Extends Relationship with LHP Hospitals but Slips Sep 05 2014
LHP Hospital Group, Inc. Expands Relationship With MedAssets to Reduce the Total Cost of Care and... Sep 03 2014
MedAssets to Participate in the FBR and Baird Investment Conferences on Sept. 3-4, 2014 Aug 29 2014
MedAssets Slips to Sell Aug 27 2014
MedAssets Signs Agreement to Acquire Sg2, Shares Slide Aug 19 2014
Will This Upgrade Help MedAssets (MDAS) Stock Today? Aug 19 2014
MEDASSETS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD... Aug 13 2014
MedAssets Signs Definitive Agreement to Acquire Sg2 Aug 13 2014
MedAssets, Inc. (NASDAQ: MDAS) to Ring The NASDAQ Stock Market Closing Bell Aug 11 2014
MEDASSETS INC Financials Aug 08 2014
MedAssets to Webcast Its 2014 Investor Day on August 13th Aug 05 2014
MedAssets to Showcase Comprehensive, Performance-Based Cost Reduction Solutions at 2014 Association... Aug 04 2014
MEDASSETS INC Files SEC form 10-Q, Quarterly Report Aug 04 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK